Leading Driver In The Sulfonamide Market 2025: Rising Market Growth Due To Increasing Antibiotic Resistance

June 20, 2025 09:01 PM AEST | By EIN Presswire
 Leading Driver In The Sulfonamide Market 2025: Rising Market Growth Due To Increasing Antibiotic Resistance
Image source: EIN Presswire

LONDON, GREATER LONDON, UNITED KINGDOM, June 20, 2025 /EINPresswire.com/ -- What Is The Growth Trajectory Of The Sulfonamide Market?
The sulfonamide market size has exhibited compelling expansion in recent years. According to the experts, it is projected to grow from a sterling $2.72 billion in 2024 to $2.91 billion in 2025 at a healthy compound annual growth rate CAGR of 7.1%. This growth, during the historical period, has been amplified by factors such as the surging predominance of bacterial infections, the persistently expanding access to generic sulfonamide drugs, attractive cost-effective treatment options, the burgeoning use in veterinary medicine, and the booming capacity of pharmaceutical manufacturing.

What Is The Projected Growth Rate And Market Size Of The Global Sulfonamide Market?
Luckily, the sulfonamides market was not a flash in the pan, and it is expected to witness intense growth in the coming years. The forecast suggests a remarkable expansion to $3.79 billion in 2029, with an impressive CAGR of 6.8%. The surge in demand for combination therapies, the mounting focus on antimicrobial resistance management, enlarged healthcare access in developing regions, thriving applications in agriculture and animal husbandry, and supportive regulatory approvals for sulfonamide formulations are all key contributors to the forecasted growth.

Get Your Free Sample Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24411&type=smp

What Is Driving The Growth Of The Sulfonamide Market?
A considerable driver propelling the growth of the sulfonamide market is the increasing prevalence of skin infections. Skin infections are conditions instigated by bacteria, viruses, fungi, or parasites invading the skin, leading to symptoms such as redness, swelling, pain, itching, or pus formation. The worrying rise in antibiotic-resistant bacteria has made common infections tougher to treat, thus increasing their propensity to spread. Sulfonamide plays a key role in treating skin infections by inhibiting bacterial growth and disrupting folic acid synthesis, making it potent against various susceptible bacteria. Particularly citing a scenario from February 2025, the American Academy of Dermatology, a US-based non-profit organization, reported that approximately 50 million Americans suffer from acne annually, making it the most predominant skin affliction in the country.

Order Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/sulfonamide-global-market-report

Which Key Industry Players Are Contributing To The Growth Of The Sulfonamide Market?
Key Industry Players within the sulfonamide market include renowned companies like Abbott Laboratories, Novartis AG, Teva Pharmaceutical Industries Limited, Intas Pharmaceuticals Limited, Cadila Pharmaceuticals Limited, Amneal Pharmaceuticals LLC, Lupin Limited, Bimeda Holdings PLC, Fera Science Limited, Virchow Laboratories Limited, Hebei Veyong Bio-Chemical Co. Ltd., Interchemie Werken De Adelaar B.V., AdvaCare Pharma, Manus Aktteva Biopharma LLP, Suleshvari Pharma, Shree Vardayini Chemical Industries Private Limited, VetOne, Zydus Cadila Healthcare Limited, Mission Pharmacal Company, Allegis Pharmaceuticals LLC.

What Are The Emerging Trends In The Sulfonamide Market?
An emerging trend witnessed in the sulfonamide market is the concerted efforts by these key players developing innovative solutions, like primary periodic paralysis PPP therapies, to diversify the therapeutic applications of sulfonamide-based drugs and cater to unmet needs in rare neuromuscular disorders. Further, major trends in the forecast period include advancements in drug delivery technologies, innovations in sulfonamide derivatives, development of targeted antibacterial therapies, ongoing research and development in antimicrobial agents, and integration of artificial intelligence in drug discovery.

How Is The Global Sulfonamide Market Segmented?
The sulfonamide market, for a comprehensive understanding, is segmented by product type into oral sulfonamides, topical sulfonamides, and injectable sulfonamides; it is further divided by chemical structure into sulfanilamide, sulfacetamide, and sulfamethoxazole. The market is segmented by application into antibacterial, antifungal, antiviral, diuretics, antidiabetic, and others; and it is also categorised by end-users, including hospitals, clinics, research laboratories, and other end users.

What Are The Regional Insights Into The Sulfonamide Market?
Shedding light on the region-wise distribution, North America was the largest region in the sulfonamide market in 2024, with Asia-Pacific expected to be the fastest-growing region in the forecast period. The sulphonamide market report covers insights across the regions of Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

Browse Through More Similar Reports By The Business Research Company:

Antibiotics Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/antibiotics-global-market-report

Carbapenem-Based Antibiotics Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/carbapenem-based-antibiotics-global-market-report

Animal Antibiotics and Antimicrobials Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/animal-antibiotics-and-antimicrobials-global-market-report

Learn More About The Business Research Company and its services. The company has published more than 15,000 reports covering 27 industries across 60+ geographies. The Business Research Company is well-known for providing comprehensive, data-rich research and insights backed by 1,500,000 datasets, comprehensive secondary research, and unique insights from industry leaders.

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
[email protected]

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.